TY - JOUR
T1 - CAPTURE ALS
T2 - the comprehensive analysis platform to understand, remedy and eliminate ALS
AU - Picher-Martel, Vincent
AU - Magnussen, Claire
AU - Blais, Mathieu
AU - Bubela, Tania
AU - Das, Samir
AU - Dionne, Annie
AU - Evans, Alan C.
AU - Genge, Angela
AU - Greiner, Russell
AU - Iturria-Medina, Yasser
AU - Johnston, Wendy
AU - Jones, Kelvin
AU - Kaneb, Hannah
AU - Karamchandani, Jason
AU - Moradipoor, Sara
AU - Robertson, Janice
AU - Rogaeva, Ekaterina
AU - Taylor, David M.
AU - Vande Velde, Christine
AU - Yunusova, Yana
AU - Zinman, Lorne
AU - Kalra, Sanjay
AU - Dupré, Nicolas
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - The absence of disease modifying treatments for amyotrophic lateral sclerosis (ALS) is in large part a consequence of its complexity and heterogeneity. Deep clinical and biological phenotyping of people living with ALS would assist in the development of effective treatments and target specific biomarkers to monitor disease progression and inform on treatment efficacy. The objective of this paper is to present the Comprehensive Analysis Platform To Understand Remedy and Eliminate ALS (CAPTURE ALS), an open and translational platform for the scientific community currently in development. CAPTURE ALS is a Canadian-based platform designed to include participants’ voices in its development and through execution. Standardized methods will be used to longitudinally characterize ALS patients and healthy controls through deep clinical phenotyping, neuroimaging, neurocognitive and speech assessments, genotyping and multisource biospecimen collection. This effort plugs into complementary Canadian and international initiatives to share common resources. Here, we describe in detail the infrastructure, operating procedures, and long-term vision of CAPTURE ALS to facilitate and accelerate translational ALS research in Canada and beyond.
AB - The absence of disease modifying treatments for amyotrophic lateral sclerosis (ALS) is in large part a consequence of its complexity and heterogeneity. Deep clinical and biological phenotyping of people living with ALS would assist in the development of effective treatments and target specific biomarkers to monitor disease progression and inform on treatment efficacy. The objective of this paper is to present the Comprehensive Analysis Platform To Understand Remedy and Eliminate ALS (CAPTURE ALS), an open and translational platform for the scientific community currently in development. CAPTURE ALS is a Canadian-based platform designed to include participants’ voices in its development and through execution. Standardized methods will be used to longitudinally characterize ALS patients and healthy controls through deep clinical phenotyping, neuroimaging, neurocognitive and speech assessments, genotyping and multisource biospecimen collection. This effort plugs into complementary Canadian and international initiatives to share common resources. Here, we describe in detail the infrastructure, operating procedures, and long-term vision of CAPTURE ALS to facilitate and accelerate translational ALS research in Canada and beyond.
KW - biomarkers
KW - CALSNIC
KW - CAPTURE
KW - open science
KW - platform
UR - http://www.scopus.com/inward/record.url?scp=85125868559&partnerID=8YFLogxK
U2 - 10.1080/21678421.2022.2041668
DO - 10.1080/21678421.2022.2041668
M3 - Article
C2 - 35195049
AN - SCOPUS:85125868559
SN - 2167-8421
VL - 24
SP - 33
EP - 39
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - 1-2
ER -